Viewray, Inc. · OTC:VRAYQ
Viewray — J.P. Morgan Healthcare Conference January 2022
26 slides from Viewray's conference presentation, Jan 13, 2022
Slide 1: J.P. Morgan Healthcare Conference January 2022
J.P. Morgan Healthcare Conference January 2022 Exhibit 99.1
Slide 2: Forward-Looking Statements
2©2022 ViewRay Technologies, Inc. All rights reserved. This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context require
Slide 3: Agenda
3 Agenda •Preliminary Q4 & FY 2021 Results •Trends in Cancer Care •Value of MRIdian Clinical, Innovation, and Commercial Pipeline •Driving Therapy Adoption and Shareholder Value
Slide 4: What We Achieved: Q4 2021 preliminary financial results
4©2022 ViewRay Technologies, Inc. All rights reserved. What We Achieved Q4 2021 preliminary financial results (unaudited) Q4 2021 Q4 2020 Change MRIdian orders 7 5 40% MRIdian backlog $313M $241M 30% Revenue $20M $18M 10% Cash usage* $7M $7M 0% (*) Excluding proceeds from equity offerings
Slide 5: What We Achieved: FY 2021 preliminary financial results
5©2022 ViewRay Technologies, Inc. All rights reserved. What We Achieved FY 2021 preliminary financial results (unaudited) FY 2021 FY 2020 Change MRIdian orders 28 17 65% MRIdian backlog $313M $241M 30% Revenue $70M $57M 23% Cash usage* $67M $70M (4%) (*) Excluding proceeds from equity offerings
Slide 6: MRIdian Therapy Adoption Journey
6©2022 ViewRay Technologies, Inc. All rights reserved. Thousands of patients with clinically reported outcomes. MRIdian Therapy Adoption Journey Systems installed(1) Patients Treated(2) Then 3 Years Ago Now (FY 2021) Growth 18k 48 4k 24 350% 100% Laying the Foundation for Growth New team in 2018/201
Slide 7: Trends in Cancer Care
7©2022 ViewRay Technologies, Inc. All rights reserved. Trends in Cancer Care
Slide 8: Global Cancer Prevalence
8©2022 ViewRay Technologies, Inc. All rights reserved. China Japan India Russia Middle East Europe S. Korea Australia/NZ North America 2.13 million 3.4 million 454 thousand 521 thousand 246 thousand 272 thousand 869 thousand 4.2 million 1.1 million 50% will receive radiation therapy at some point du
Slide 9: Radiation Oncology Market Opportunity
9©2022 ViewRay Technologies, Inc. All rights reserved. Radiation Oncology Market Opportunity ~$6.5B Global radiotherapy market in 2023 (projected)1 Installed base2 ~14,000 Replacment2 800/year De novo units 2 200/year ~1,000 – 1,250 LINAC units sold / year2 * See citations in appendix
Slide 10: MRIdian Paradigm Change is Clear
10©2022 ViewRay Technologies, Inc. All rights reserved. MRIdian Paradigm Change is Clear * See citations in appendix
Slide 11: Dose vs. toxicity paradigm
11©2022 ViewRay Technologies, Inc. All rights reserved. Dose vs. toxicity paradigm Lower dose ~20-40 treatments Pancreas survival: 12-15 mons. Paradigm broken – ablative dose, low to no grade 3+ toxicity Conventional MRIdian1 Paradigm shift is clear > > > Ablative dose 5 or fewer Tx Median pancreas
Slide 12: Customers' Definition of Clinical Success
12©2022 ViewRay Technologies, Inc. All rights reserved. Customers’ Definition of Clinical Success The MRIdian 51 Ablative dose 1 Tight margins 2 No fiducials 3 5 or fewer fractions 4 No to low grade 3+ toxicity 5 Among alternatives in the clinical landscape, we have found MRIdian’s evidence fits thi
Slide 13: MRIdian Value Chain
13©2022 ViewRay Technologies, Inc. All rights reserved. MRIdian Value Chain Customers are purchasing multiple MRIdian systems = Top and bottom line impact for customers +MRIdian 51 1 2 3 5 4 Ablative dose Tight margins No fiducials 5 or fewer fractions No or low grade 3 toxicity Clinical Strategic E
Slide 14: Focused-Beachhead Patient-Centric Roadmap
14©2022 ViewRay Technologies, Inc. All rights reserved. Focused-Beachhead Patient-Centric Roadmap Bone #1 #2 #3 #4 Expand utilization of MRIdian SMART Become first line therapy PANCREAS PROSTATE LUNG BRAIN GI GU Thoracic Cranial
Slide 15: MRIdian Clinical Pipeline
15©2022 ViewRay Technologies, Inc. All rights reserved. MRIdian Clinical Pipeline Constant flow of proof to drive adoption • Prospective studies. Larger ‘N’ • Confirm signals in key tumor sites • Safety and Efficacy endpoints • Randomized controlled trials • Comparative • Safety and efficacy endpoin
Slide 16: Recent Clinical Data Event
16©2022 ViewRay Technologies, Inc. All rights reserved. Recent Clinical Data Event Michael Chuong, MD, FACRO Vice Chair, Medical Director, Clinical Research Director, Lead GI Radiation Oncologist - Dept of Radiation Oncology at Miami Cancer Institute • 148 patients from 3 institutions ◦ All treated
Slide 17: Recent Clinical Data Event: Evolution of prostate treatment
17©2022 ViewRay Technologies, Inc. All rights reserved. Recent Clinical Data Event Evolution of prostate treatment1 Himanshu Nagar, MD Assistant Professor, Department of Radiation Oncology at Weill Cornell Medicine NewYork-Presbyterian • X-ray to MRI • Real-time MRI is future • SHORTER – Post-op Pro
Slide 18: MRIdian Target
MRIdian Target Demonstrate safety of MRIdian SMART to treat what others can’t. Prostate • MIRAGE – Released at ASCO GU in February 2022 • SCIMITAR & SHORTER – Demonstrate the safety of 5fx SBRT in post-op prostate • FORT - Redefine standard prostate treatment from 5fx to 2fx Mission: Improve patient
Slide 19: Newest Generation of Innovations – MRIdian A3i System
Newest Generation of Innovations – MRIdian A3i System •Workflow efficiency ◦ Streamline adaptive workflow ◦ Integrate auto-contouring ◦ Remote, parallel workflow ◦ Enable increased patient throughput • Clinical utility ◦ Brain treatment package ◦ New imaging and planning scans ◦ 3D multiplanar track
Slide 20: Recent Highlights
20©2022 ViewRay Technologies, Inc. All rights reserved. Recent Highlights Innovation and clinical pipelines accrue customer traction Clinical ASTRO Pancreas Data Innovation 510(k) Clearance on MRIdian A3i System Commercial Customers purchasing multiple systems: TJU, Baptist Health South Florida and
Slide 21: Positioned for Growth & Therapy Adoption
21©2022 ViewRay Technologies, Inc. All rights reserved. Thousands of patients with clinically reported outcomes. MRIdian Therapy Adoption Journey Now (FY 2021) Future (2-4 years) 18k 48 2x (again) 4x (again) Positioned for Growth & Therapy Adoption • Innovation pipeline accelerating • Clinical data
Slide 22: ViewRay | Visibly Better
@ VIEW RAY | VISIBLY BETTER
Slide 23: Appendix
> vIEwRAY Appendix
Slide 24: Citations
24©2022 ViewRay Technologies, Inc. All rights reserved. Slide 6: 1. Internal and historical company data 2. 12/31/2021 MRIdian log data Slide 8: 3. https://jamanetwork.com/journals/jamaoncology/fullarticle/2787350 4. https://www.medsci.org/v09p0193.htm 5. https://pubmed.ncbi.nlm.nih.gov/16080176/ Sl
Slide 25: Citations
25©2022 ViewRay Technologies, Inc. All rights reserved. Slide 12 1. Ablative dose, Tight margins, No fiducials: Chuong MD, Bryant J, Mittauer KE, Hall M, Kotecha R, Alvarez D, Romaguera T, Rubens M, Adamson S, Godley A, Mishra V, Luciani G, Gutierrez AN, Ablative 5-fraction stereotactic magnetic res
Slide 26: Presentation Citations
26©2022 ViewRay Technologies, Inc. All rights reserved. Presentation Citations Slide 15 and Slide 18 1. Phase 1 (Exploratory) - SMART ONE: Miami Cancer Institute, PI: Dr. Michael Chuong, “Stereotactic MRI-Guided Adaptive Radiation Therapy Delivered in One Fraction for Inoperable Primary or Metastati
ViewRay — J.P. Morgan Healthcare Conference January 2022 on 6ix